Dapagliflozin (Farxiga, AstraZeneca/Bristol-Myers Squibb), from one of the newer classes of type 2 diabetes drugs, may have potential as add-on therapy for treating ...
PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)-- Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug ...
Amit Bansal, Managing Director, Theon Pharmaceuticals Ltd says this fixed-dose combination tablet of linagliptin, dapagliflozin, and metformin hydrochloride is a suitable option for the following ...
Dapagliflozin, metformin HCl ext-rel; 2.5mg/1000mg, 5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg; tabs. Xigduo® XR (dapagliflozin and metformin HCl extended-release) tablets have markings on one ...
The kidneys filter and resorb approximately 180 g of glucose per day, using the 2 sodium-dependent glucose transporters (SGLT1 and SGLT2) in the proximal tubule. Of these, SGLT2 is responsible for the ...
The FDA approved AstraZeneca’s Farxiga (dapagliflozin) for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults with and without type 2 diabetes (T2D). It's the first SGLT2 ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Patients with type 1 diabetes treated with insulin and liraglutide with the addition of Farxiga ...
Dapagliflozin substantially slowed the progression of chronic kidney disease (CKD) in patients with immunoglobulin A nephropathy, according to a new study. Treatment with dapagliflozin substantially ...
At week 24, the decrease in adjusted mean total body weight, a secondary endpoint, was greater with each dapagliflozin dose compared to placebo, although not reaching statistical significance (-3.3 kg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback